Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.62 |
| ▸ | FAAH | O00519 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769868 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL30349 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL9800921 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL31348788 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL25711820 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL3096362 | 1.00 | SLC6A5 (0.62) | SLC6A5FAAHMEN1TP53CYP1A2 | |
| SCHEMBL5146257 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL6332840 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL29619662 | 0.95 | KDM4E (0.65) | SOAT1KDM4E | |
| SCHEMBL1702127 | 0.91 | EPHX2 (0.60) | SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0297610-B1 | N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase | WARNER-LAMBERT COMPANY (US) | 1991-03-13 | — | — | EP | claimed |
| EP-0297610-A1 | N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase | WARNER-LAMBERT COMPANY (US) | 1989-01-04 | — | — | EP | claimed |
| US-12521350-B2 | Liquid crystalline dosage form for administering a statin | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-12521342-B2 | Fast disintegrating tablet | CUBOPHARM PTY LTD (AU) | 2026-01-13 | — | — | US | disclosed |
| US-20240366510-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | ZEENAR ENTERPRISES PTY LTD (AU) | 2024-11-07 | — | — | US | disclosed |
| US-20240350405-A1 | FAST DISINTEGRATING TABLET | ZEENAR ENTERPRISES PTY LTD (AU) | 2024-10-24 | — | — | US | disclosed |
| WO-2023210218-A1 | LUBRICATING OIL COMPOSITION | ＥＮＥＯＳ株式会社 | 2023-11-02 | — | — | WO | disclosed |
| US-20230277463-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | ZEENAR ENTERPRISES PTY LTD (AU) | 2023-09-07 | — | — | US | disclosed |
| US-11638698-B2 | Liquid crystalline dosage form for administering a statin | ZEENAR ENTERPRISES PTY LTD (AU) | 2023-05-02 | — | — | US | disclosed |
| CN-112912477-B | Lubricating oil composition | 引能仕株式会社 | 2022-11-11 | — | — | CN | disclosed |
| CN-112912478-B | Lubricating oil composition | 引能仕株式会社 | 2022-11-08 | — | — | CN | disclosed |
| EP-1534669-A4 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | MAYNE PHARMA INT PTY LTD (AU) | 2007-03-14 | — | — | EP | disclosed |
| US-20060172900-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION | NIPPON OIL CORPORATION (JP) | 2006-08-03 | — | — | US | disclosed |
| EP-1686167-A1 | LUBRICATING OIL ADDITIVE AND LUBRICATING OIL COMPOSITION | Nippon Oil Corporation (JP) | 2006-08-02 | — | — | EP | disclosed |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | DBL AUSTRALIA PTY LTD. (AU) | 2005-11-10 | — | — | US | disclosed |
| EP-1534669-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL Australia PTY. LTD. (AU) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004022530-A1 | UREA-, GLYCERATE- AND, HYDROXYAMIDE-HEADED HYDROCARBON CHAIN LYOTROPIC PHASES FORMING SURFACTANTS | DBL AUSTRALIA PTY LTD (AU) | 2004-03-18 | — | — | WO | disclosed |
| US-5358652-A | Using 3,5-dihydrocarbyl-4-hydroxybenzylamine compound | ETHYL PETROLEUM ADDITIVES, LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| EP-0297610-B1 | N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase | WARNER-LAMBERT COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| EP-0297610-A1 | N-[(2,6-disubstituted)phenyl]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase | WARNER-LAMBERT COMPANY (US) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366510-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | HMGCR, LIPA, NPC1L1 | SLC6A5 2257/4885FAAH 3027/4885MEN1 2115/4885 |
| US-20230277463-A1 | LIQUID CRYSTALLINE DOSAGE FORM FOR ADMINISTERING A STATIN | HMGCR, LIPA, NPC1L1 | SLC6A5 2257/4885FAAH 3027/4885MEN1 2115/4885 |
| US-20050249665-A1 | Urea-, glycerate- and, hydroxyamide-headed hydrocarbon chain lyotropic phases forming surfactants | LIPA, HDHD5, UGCG | SLC6A5 1081/4885FAAH 41/4885MEN1 3636/4885 |
| US-11638698-B2 | Liquid crystalline dosage form for administering a statin | HMGCR, LIPA, NPC1L1 | SLC6A5 2257/4885FAAH 3027/4885MEN1 2115/4885 |
| US-20240350405-A1 | FAST DISINTEGRATING TABLET | SI, DSC1, STOM | SLC6A5 2804/4885FAAH 2990/4885MEN1 2994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.